BASF, The Chemical Company
116 articles about BASF, The Chemical Company
-
“Humira is an anti-TNF monoclonal antibody that currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those...
-
BASF clinical trial reveals significant reduction in liver fat content in patients with non-alcoholic fatty liver disease
10/29/2018
BASF AS completed a randomized, placebo-controlled clinical trial in the U.S., newly published in Nutrients, evaluating the use of high concentrate omega-3 to correct the nutritional deficiency of omega-3 fatty acid in patients with non-alcoholic fatty liver disease (NAFLD). Several studies have shown that NAFLD patients have lower levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)i.
-
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
-
One Company Owns Almost Half of Marine Gene Sequence Patents: What It Could Mean for Drug Discovery
10/2/2018
German chemical company BASF, the world’s largest chemical producer, has registered 47 percent of patented marine organism gene sequences, according to a study published in Science Advances in June. -
BASF expands vitamin A plant in Ludwigshafen
9/14/2018
BASF has started the expansion of its vitamin A plant at the company’s Ludwigshafen site.
-
Benefits of omega-3 long-chain fatty acids in patients with non-alcoholic fatty liver disease revealed in meta-analysis of 18 studies
8/16/2018
Nutrition Reviews® published a systematic review and meta-analysis of 18 controlled intervention studies on the effectiveness of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) in patients with non-alcoholic fatty liver disease (NAFLD).
-
Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.
-
BASF Further Expands Production Capacity At Specialty Amines Complex In Nanjing, China
9/25/2017
-
BASF Increases Prices For Ethanolamines In Europe
9/21/2017
-
BASF Expands Portfolio Of Amines
9/7/2017
-
BASF And Kaiima Bio-Agritech Ltd. Announce Collaboration To Identify Novel Herbicide Resistance Traits Using The EP Technology Platform
7/17/2017
-
BASF Plans Significant Investment In Ibuprofen Capacities In Germany And North America
6/28/2017
-
BASF To Increase Prices For Butanediol And Derivatives In Europe
6/1/2017
-
BASF Launches New MasterTop Flooring Series On The European Market
4/13/2017
-
BASF Increases Prices For Ethanolamines In Europe
3/15/2017
-
BASF Inorganic Specialties Divestiture Creates New Business Named Callery
3/14/2017
-
BASF To Increase Prices For Butanediol And Derivatives In Europe
3/1/2017
-
BASF Release: Company And Nuritas To Work Together On Delivering Next Generation Peptide Ingredients Through Artificial Intelligence
1/18/2017
-
BASF Launches Ucrete MF40AS Industrial Flooring System On The European Market
12/7/2016
-
BASF To Increase Prices For Butanediol And Derivatives In Europe
12/1/2016